Physician profile
Grant A Partin
NPI 1992247530
$3,657.37
in general payments reported to CMS, 2019-2025
23 companies · $1,795 in 2025
The $1,795 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.53 · 2022: $344 · 2023: $1,185 · 2024: $301 · 2025: $1,795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,944 · Education: $337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,944.18 |
| Education | $336.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $688.72 | 2021-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $544.85 | 2024-2025 | Lumryz |
| Axsome Therapeutics, INC. | $410.10 | 2023-2025 | Sunosi |
| Harmony Biosciences LLC | $329.75 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $324.60 | 2022-2023 | Lifevest |
| Amgen INC. | $309.86 | 2022-2023 | Repatha |
| Inspire Medical Systems, INC. | $303.81 | 2024-2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $141.11 | 2023 | Camzyos |
| Philips North America LLC | $90.50 | 2023-2024 | (7999) Src Und |
| Pfizer INC. | $77.37 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $72.75 | 2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $51.16 | 2022-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.54 | 2023 | Jardiance |
| Fisher & Paykel Healthcare INC | $36.12 | 2025 | Fisher & Paykel Healthcare |
| Impulse Dynamics (USA) INC. | $33.34 | 2023 | Optimizer |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $33.07 | 2022-2023 | Ozempic, Rybelsus |
| 3b Medical, INC. | $29.84 | 2025 | Luna |
| Kiniksa Pharmaceuticals, LTD. | $29.75 | 2023 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $28.64 | 2023 | Evkeeza |
| Daiichi Sankyo INC. | $23.69 | 2023 | Injectafer |
| Merck Sharp & Dohme LLC | $18.12 | 2023 | Verquvo |
| Resmed Corp | $16.54 | 2025 | |
| Novartis Pharmaceuticals Corporation | $16.14 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grant Partin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.